Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has announced that the Japanese Ministry of Health, Labor and Welfare has granted an approval for use of Taxotere injection in prostate cancer.
Subscribe to our email newsletter
Taxotere is already approved in Japan for the treatment of breast cancer, non-small cell lung, gastric, head and neck, ovarian, esophageal and endometrial cancers.
This new approval is based on the results of an international large-scale Phase III clinical study TAX327 and on a Japanese Phase II clinical trial.